{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Quarfloxin",
  "nciThesaurus": {
    "casRegistry": "865311-47-3",
    "chebiId": "",
    "chemicalFormula": "C35H33FN6O3",
    "definition": "A fluoroquinolone derivative with antineoplastic activity. Quarfloxin disrupts the interaction between the nucleolin protein and a G-quadruplex DNA structure in the ribosomal DNA (rDNA) template, a critical interaction for rRNA biogenesis that is overexpressed in cancer cells; disruption of this G-quadruplex DNA:protein interaction in aberrant rRNA biogenesis may result in the inhibition of ribosome synthesis and tumor cell apoptosis.",
    "fdaUniiCode": "8M31J5031Q",
    "identifier": "C71726",
    "preferredName": "Quarfloxin",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C25995",
      "C52588"
    ],
    "synonyms": [
      "3H-Benzo(b)pyrido(3,2,1-kl)phenoxazine-2-carboxamide, 5-fluoro-N-(2-((2S)- 1-methyl-2-pyrrolidinyl)ethyl)-3-oxo-6-(3-pyrazinyl-1-pyrrolidinyl)-",
      "5-Fluoro-N-(2-((2S)-1-methylpyrrolidin-2-yl)ethyl)-3-oxo-6-(3-(pyrazin-2- yl)pyrrolidin-1-yl)-3H-benzo(b)pyrido(3,2,1-kl)phenoxazine-2-carboxamide",
      "CX-3543",
      "QUARFLOXIN",
      "Quarfloxacin",
      "Quarfloxin"
    ]
  }
}